{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.8","value":"4.0"},{"groupId":"OG001","spread":"3.2","value":"3.9"},{"groupId":"OG002","spread":"3.0","value":"3.3"},{"groupId":"OG003","spread":"3.3","value":"3.6"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.9","value":"3.5"},{"groupId":"OG001","spread":"2.8","value":"3.5"},{"groupId":"OG002","spread":"3.0","value":"3.4"},{"groupId":"OG003","spread":"3.1","value":"3.6"}]}],"title":"Pre-cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.1","value":"3.6"},{"groupId":"OG001","spread":"2.7","value":"4.0"},{"groupId":"OG002","spread":"3.0","value":"3.5"},{"groupId":"OG003","spread":"3.0","value":"2.5"}]}],"title":"Pre-cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.0","value":"2.3"},{"groupId":"OG001","spread":"2.9","value":"3.2"},{"groupId":"OG002","spread":"3.0","value":"3.7"},{"groupId":"OG003","spread":"2.7","value":"2.9"}]}],"title":"9 months post cycle 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"86"},{"groupId":"OG003","value":"92"}],"units":"Participants"}],"description":"Single item from the Brief Pain Inventory (BPI) assessing \"worst pain\" in the past 24 hours, on a 0-10 scale with a higher score indicating more pain than a low score.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.\n\nCisplatin: Given IV\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Arm I (Paclitaxel, Cisplatin)"},{"description":"Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.\n\nCisplatin: Given IV\n\nQuality-of-Life Assessment: Ancillary studies\n\nVinorelbine Tartrate: Given IV","id":"OG001","title":"Arm II (Vinorelbine, Cisplatin)"},{"description":"Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.\n\nCisplatin: Given IV\n\nGemcitabine Hydrochloride\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG002","title":"Arm III (Gemcitabine, Cisplatin)"},{"description":"Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.\n\nCisplatin: Given IV\n\nQuality-of-Life Assessment: Ancillary studies\n\nTopotecan Hydrochloride: Given IV","id":"OG003","title":"Arm IV (Topotecan, Cisplatin)"}],"paramType":"MEAN","populationDescription":"Patients who provided baseline and ≥ one follow-up assessments","reportingStatus":"POSTED","timeFrame":"Baseline (pre-cycle 1), Pre-cycle 2, Pre-cycle 5, 9 months post cycle 1","title":"Pain, Assessed by Brief Pain Inventory","type":"SECONDARY","unitOfMeasure":"units on a scale"}